Pediatrix Medical Group (NYSE:MD) Given New $15.00 Price Target at Deutsche Bank Aktiengesellschaft

Pediatrix Medical Group (NYSE:MD) had its target price upped by Deutsche Bank Aktiengesellschaft from $9.00 to $15.00 in a research note issued to investors on Monday morning, Benzinga reports. The brokerage currently has a hold rating on the stock.

MD has been the topic of a number of other reports. StockNews.com raised Pediatrix Medical Group from a “sell” rating to a “hold” rating in a report on Wednesday, August 7th. Truist Financial upped their price target on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a report on Monday. UBS Group upped their price target on Pediatrix Medical Group from $9.00 to $10.50 and gave the company a “neutral” rating in a report on Friday, August 9th. Jefferies Financial Group raised Pediatrix Medical Group from a “hold” rating to a “buy” rating and upped their price target for the company from $8.00 to $14.00 in a report on Thursday, September 26th. Finally, Mizuho upped their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Monday. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $14.90.

Pediatrix Medical Group Stock Up 0.3 %

Shares of NYSE MD traded up $0.05 during trading on Monday, reaching $15.19. The company had a trading volume of 33,721 shares, compared to its average volume of 869,003. Pediatrix Medical Group has a 12-month low of $6.62 and a 12-month high of $15.43. The stock has a market cap of $1.30 billion, a PE ratio of -4.95, a P/E/G ratio of 2.36 and a beta of 1.55. The business’s 50-day moving average is $11.70 and its 200 day moving average is $9.45. The company has a quick ratio of 1.38, a current ratio of 1.58 and a debt-to-equity ratio of 0.86.

Pediatrix Medical Group (NYSE:MD) last released its earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The firm had revenue of $511.20 million for the quarter, compared to analysts’ expectations of $498.87 million. During the same period in the prior year, the firm posted $0.29 earnings per share. The company’s quarterly revenue was up .9% on a year-over-year basis. As a group, equities analysts forecast that Pediatrix Medical Group will post 1.19 earnings per share for the current fiscal year.

Insider Buying and Selling at Pediatrix Medical Group

In other news, Director Laura A. Linynsky sold 7,000 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the transaction, the director now owns 30,805 shares of the company’s stock, valued at $343,783.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Pediatrix Medical Group news, Director Laura A. Linynsky sold 7,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total transaction of $78,120.00. Following the completion of the transaction, the director now owns 30,805 shares in the company, valued at $343,783.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO C Marc Richards sold 17,438 shares of Pediatrix Medical Group stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $10.08, for a total value of $175,775.04. Following the completion of the transaction, the chief financial officer now owns 175,347 shares of the company’s stock, valued at approximately $1,767,497.76. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 68,100 shares of company stock valued at $701,889. 1.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Pediatrix Medical Group

A number of institutional investors and hedge funds have recently bought and sold shares of MD. Rubric Capital Management LP increased its holdings in shares of Pediatrix Medical Group by 797.0% in the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock valued at $61,532,000 after acquiring an additional 7,241,400 shares during the period. Dana Investment Advisors Inc. increased its holdings in shares of Pediatrix Medical Group by 80.3% in the 2nd quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock valued at $7,725,000 after acquiring an additional 455,785 shares during the period. Boston Partners increased its holdings in shares of Pediatrix Medical Group by 34.0% in the 1st quarter. Boston Partners now owns 1,786,434 shares of the company’s stock valued at $17,702,000 after acquiring an additional 453,254 shares during the period. Cubist Systematic Strategies LLC increased its holdings in shares of Pediatrix Medical Group by 639.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock valued at $2,192,000 after acquiring an additional 251,072 shares during the period. Finally, ClariVest Asset Management LLC purchased a new position in shares of Pediatrix Medical Group in the 2nd quarter valued at $1,721,000. 97.71% of the stock is owned by institutional investors.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.